GlycoMimetics - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi GLYC

GlycoMimetics, Inc. (GLYC) possesses significant potential driven by its leukemia patents, as evidenced by the company's EBITDA. The value of reflects this status. However, risks remain tied to the dependence on the small-molecule R&D platform and a lack of revenue, meaning that expanding the drug portfolio only increases current laboratory expenses.

GlycoMimetics Inc. - Bathi operasional EBITDA GLYC (periode 04.07.2022 - 10.11.2026)

GlycoMimetics (GLYC) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Rega bursa GlycoMimetics Inc.|GLYC - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar GlycoMimetics|GLYC - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Rega Buku Saham GlycoMimetics|GLYC - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku glycomimetics.com|GLYC - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi GlycoMimetics, Inc.|GLYC - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas GlycoMimetics Inc.|GLYC - Gunggung utang perusahaan|Utang-utang marang nilai buku GlycoMimetics|GLYC - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak GlycoMimetics|Likuiditas darurat glycomimetics.com

- rincian asil keuangan lan kelipatan valuasi:

GLYC - Bathi resik|Prakiraan bathi resik GlycoMimetics, Inc.|GLYC - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi GlycoMimetics Inc.|GLYC - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan GlycoMimetics|GLYC - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku GlycoMimetics|GLYC - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan glycomimetics.com|GLYC - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep GlycoMimetics, Inc.

Ringkesan analitik perusahaan:GlycoMimetics, Inc.

Institutional capital assesses the investment attractiveness of GlycoMimetics, Inc. (GLYC) through the lens of the business's ability to generate real cash flow before taxes and depreciation. Monitoring EBITDA_Co allows for the exclusion of accounting adjustments, which is critical for a biotech firm facing drug trial failures and the need for emergency liquidity management to ensure the asset's survival.

Analisis pesaing GlycoMimetics, Inc.